uniQure vs Voyager Therapeutics
QURE and VYGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QURE and VYGR compare
uniQure is the larger company, worth 15 times as much as Voyager Therapeutics ($1.7B against $107M).
uniQure grew revenue faster over the last twelve months (28.0% versus −19.8% for Voyager Therapeutics).
Voyager Therapeutics keeps more of each dollar of sales as profit, with a net margin of −416% compared with −1155% at uniQure.
Voyager Therapeutics scores higher on the StockData Score (8 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QURE | VYGR |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $107M |
| Share price | $23.81 | $1.73 |
| Change, 1 year | −20.9% | −59.3% |
| Change, 5 years | −19.7% | −47.4% |
| Beta (5Y) | 1.67 | 1.19 |
| Employees | 221 | 141 |
| StockData Score | ||
| Total score | 4 | 8 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 81.9× | 4.2× (better) |
| P/B | 5.6× | 0.8× (better) |
| FCF yield | −11.7% (better) | −103% |
| Fair value | $5.95 | $2.87 |
| Margin of safety | −300% | 39.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 28.0% (better) | −19.8% |
| Revenue growth, 5Y average | −15.6% (better) | −25.1% |
| Profitability | ||
| Gross margin | 93.9% | – |
| Operating margin | −1002% | −450% (better) |
| Net margin | −1155% | −416% (better) |
| FCF margin | −957% | −437% (better) |
| Return on equity | −89.0% | −58.9% (better) |
| Financial health | ||
| Debt / equity | 0.17 (better) | 0.00 |
| Interest coverage | −3.5× | – |
| Current ratio | 11.52 (better) | 6.81 |
| Altman Z-score | −0.62 (better) | −3.91 |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 96.0% | 56.9% |
| Held by insiders | 2.1% | 2.6% |
| Insider net buying, 12 months | −$20.2M | −$298K (better) |
| Short interest, % of float | 12.5% | 7.3% |
Go deeper
- QURE stock overview
- QURE income statement
- QURE valuation and score
- VYGR stock overview
- VYGR income statement
- VYGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.